Back to School: How biopharma can reboot drug development. Access exclusive analysis here
David MacCallum, formerly co-head of investment banking at Hambrecht & Quist, has moved to
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury